Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet].

This Rapid Response report aims to review the clinical effectiveness and safety of 3- month injectable paliperidone palmitate (PP3M) for schizophrenia compared with once-monthly injectable formulation (PP1M) and placebo in the treatment of adults with schizophrenia. Evidence-based guidelines regarding the use of 3-month injectable paliperidone palmitate for the adults with schizophrenia will also be examined.

https://ift.tt/2LUKrpA